PHARMAC is seeking feedback on a proposal to list a range of wound care products supplied by Mölnlycke Health Care Pty Limited (“Mölnlycke”) in Part III of Section H of the Pharmaceutical Schedule from 1 February 2014. In summary, this proposal would result in:
• Around 200 wound care products which are already supplied to some DHB Hospitals being supplied under a proposed national agreement that all DHBs may purchase under, subject to consultation and approval (“Agreement”). This Agreement is not a sole supply agreement, and DHBs may continue to purchase other suppliers brands of wound care products.
• Mölnlycke providing educational services including information on indications, contraindications and appropriate use of the wound care products included in the Agreement, to be organised with each DHB to suit its needs.
• Estimated total savings to DHBs of approximately $160,000 per annum based on current usage. Pricing for wound care products in the Agreement, subject to any prior termination of the Agreement would not be increased before January 2017.
Feedback Due: to Policy analyst Marilyn Head firstname.lastname@example.org, 04 494 6372 by December 18th, 2013.